Compare Accenture plc (ACN) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Accenture plc vs AstraZeneca plc — how do they compare? Accenture plc trades at $138.61 (market cap $86.98B), while AstraZeneca plc trades at $189.93 (market cap $294.08B). The key difference: AstraZeneca plc is far larger — about 3.4× Accenture plc's market cap, and Accenture plc pays the higher dividend (4.59%). Which is the better fit depends on your goals.
| ACN | AZN | |
|---|---|---|
Market Cap | $86.98B | $294.08B |
Sector | Technology | Health |
52-Week High | $303.33 | $209.48 |
52-Week Low | $124.41 | $137.44 |
Enterprise Value | $85.20B | $320.32B |
Dividend Yield | 4.59% | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
AstraZeneca (AZN) trades at $193.12, down 1.04% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, marking a 17.4% profit margin. Recent news highlights strategic collaborations and regulatory approvals for key drugs like Enhertu, reinforcing growth prospects.
AZN presents a favorable outlook with robust earnings growth and a solid pipeline, though valuation multiples like a P/E of 28.64 suggest premium pricing. Risks include competitive pressures and trial outcomes, but analyst consensus leans bullish with 47.5% buy ratings. Institutional interest remains high, supporting potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Accenture plc
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
